|
|
Expression levels of serum pentraxin 3 and fibroblast growth factor 2 in patients with chronic heart failure and their correlation with myocardial remodeling and cardiac function |
YU Hongbo1 LIU Yaqun2 YIN Dong3 |
1.Department of Cardiology, Qinhuangdao Jungong Hospital, Hebei Province, Qinhuangdao 066000, China;
2.Department of Neurology, Qinhuangdao Jungong Hospital, Hebei Province, Qinhuangdao 066000, China;
3.Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100000, China |
|
|
Abstract Objective To detect the expression levels of serum pentagerin 3 (PTX3) and fibroblast growth factor 2 (FGF2) in patients with chronic heart failure (CHF), and to analyze the relationship between them and myocardial remodeling and cardiac function. Methods A total of 89 CHF patients in Qinhuangdao Jungong Hospital (hereinafter referred to as “our hospital”) from April 2018 to May 2019 were selected as the research subjects, and they were taken as the experimental group, and 90 healthy subjects in our hospital during the same period were taken as the control group. According to cardiac function status, CHF patients were divided into gradeⅠ(14 cases), grade Ⅱ(18 cases), grade Ⅲ (31 cases), and grade Ⅳ (26 cases). Serum PTX3 and FGF2 levels of the included subjects were detected. The relationship between cardiac function grade and serum PTX3 and FGF2 levels was analyzed. The relationship between the serum levels of PTX3, FGF2 and cardiac function and myocardial remodeling in CHF patients was analyzed. Results Serum levels of the serum level of PTX3 and FGF2 in experimental group were higher than those in the control group (P < 0.05). In patients with CHF, compared with grade Ⅰ, serum levels of PTX3 and FGF2 were increased in patients with grades Ⅱ, Ⅲ, Ⅳ (P < 0.05). Compared with grade Ⅱ, the serum levels of PTX3 and FGF2 were increased in patients with grade Ⅳ(P < 0.05). Compared with grade Ⅲ, the serum levels of PTX3 and FGF2 were increased in patients with grade Ⅳ (P < 0.05). Compared with gradeⅠ, the left ventricular end diastolic dimension (LVEDD) and left atrium diameter (LAD) in patients with grades Ⅱ, Ⅲ, Ⅳ, left ventricular mass index (LVMI) in patients with grade Ⅳ were increased, left ventricular cardiac output (LVCO) in patients with grades Ⅲ, Ⅳ, left ventricular ejection fraction (LVEF) and left ventricular reconstruction index (LVRI) in patients with grade Ⅳ were decreased (P < 0.05). Compared with grade Ⅱ, the LVEDD and LAD in patients with grade Ⅳ were increased, the LVCO in patients with gradesⅢ, Ⅳ, the LVEF in patients with grade Ⅳ were decreased (P < 0.05). Compared with grade Ⅲ, the LVEDD and LAD in patients with grade Ⅳ were increased, the LVCO and LVEF were decreased (P < 0.05). Serum level of PTX3 in CHF patients was positively correlated with LVEDD and LVMI, and negatively correlated with LVEF and LVCO (P < 0.05); the level of FGF2 was positively correlated with LVEDD, LAD and LVMI, and negatively correlated with LVEF and LVERI (P < 0.05). Conclusion The elevated serum levels of PTX3 and FGF2 in CHF patients are closely related to cardiac function and myocardial remodeling indexes, and affect the severity of the disease.
|
|
|
|
|
[1] 王蕾,王学惠,潘亚婷,等.LIPCAR在慢性心力衰竭及合并肾功能不全患者循环中的表达[J].中国动脉硬化杂志,2018,26(4):384-388.
[2] Mao GX,Cao YB,Yang Y,et al. Additive benefits of twice forest bathing trips in elderly patients with chronic heart failure [J]. Biomed Environ Sci,2018,31(2):159-162.
[3] 徐振宇,杨立明,李广平,等.慢性心力衰竭患者血清miR-133 a、miR-133 b水平与心功能和心肌重构的关系[J].山东医药,2018,58(4):82-84.
[4] 石宝星,胡伟.芪苈强心胶囊联合心脏康复对慢性心力衰竭患者心功能和心室重构的影响[J].中国循证心血管医学杂志,2020,12(4):470-472.
[5] 柳敏娜,王谨涵,潘刚,等.诃子酸抗肾间质纤维化的作用及机制研究[J].解放军医药杂志,2020,32(6):1-5,13.
[6] Adeyemo A,Johnson C,Stiene A,et al. Limb functional recovery is impaired in fibroblast growth factor-2(FGF2)deficient mice despite chronic ischaemia-induced vascular growth [J]. Growth Factors,2020,38(2):75-93.
[7] 李涛,张菲斐,魏经汉.慢性心力衰竭患者血浆正五聚蛋白3水平的临床观察[J].临床荟萃,2010,25(5):18-20.
[8] 张廷川,赵德强.正五聚蛋白3在防治心血管疾病中的研究进展[J].岭南心血管病杂志,2019,25(6):714-717.
[9] 梅黎,李飞,苏伟,等.靶向siRNA沉默长正五聚蛋白3对主动脉瓣膜间质细胞表达炎症细胞因子的影响[J]. 华中科技大学学报:医学版,2019,48(5):497-502.
[10] 中华医学会心血管病学分会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[11] Johnson MJ,Bland JM,Davidson PM,et al. The relationship between two performance scales:New York Heart Association Classification and Karnofsky Performance Status Scale [J]. J Pain Symptom Manage,2014,47(3):652-658.
[12] 心力衰竭超滤治疗专家组.心力衰竭超滤治疗建议[J].中华心血管病杂志,2016,44(6):477-482.
[13] 李晓瑶,赵爽,樊晓寒,等.血浆大内皮素-1对心力衰竭患者心脏性猝死的预测价值[J].中华心律失常学杂志,2021,25(1):67-72.
[14] 李亚南,崔存英,刘园园,等.血流向量成像对慢性心力衰竭患者左心室舒张功能的研究[J].中国医学影像学杂志,2019,27(5):328-332.
[15] 胡玉藏,倪文璐.超声VVI技术联合Tei指数对肝内胆汁淤积症孕妇胎儿心功能异常的检测价值[J].肝脏,2020,25(5):541-544.
[16] 邵玲,周梦桥,熊涛,等.杨梅素通过激活AKT信号通路抑制心肌梗死后心脏重构的研究[J].重庆医学,2019,48(11):1817-1821.
[17] 杨静,高日扬,黎云,等.大剂量培哚普利动员内皮祖细胞对心肌梗死后心力衰竭患者心功能的影响[J].内科急危重症杂志,2020,26(01):50-52,65.
[18] Soupene E,Larkin SK,Kuypers FA. Depletion of HDL 3 high density lipoprotein and altered functionality of HDL 2 in blood from sickle cell patients [J]. Exp Biol Med(Maywood),2017,242(12):1244-1253.
[19] 刁嘉乐,魏锐利.穿透素3对转化生长因子β1诱导的眼眶成纤维细胞纤维化的影响[J].第二军医大学学报,2020,368(4):82-86.
[20] 曹端华,闫海燕,王婷婷,等.血浆正五聚蛋白3水平与颈动脉粥样硬化斑块稳定性的相关性研究[J].中国医药,2019,14(3):367-370.
[21] 林朴卿,齐悦,张良珍,等.血浆CPP、PTX3水平对稳定性冠心病患者冠状动脉狭窄的诊断价值[J].山东医药,2020,60(10):27-31.
[22] 高慧阳.盐酸曲美他嗪对冠状动脉粥样硬化性心脏病患者血脂、心肌损伤及心肌能量代谢的影响[J].中国临床医生杂志,2020,48(07):806-809.
[23] 江涛,廖英坚.前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果[J].中国当代医药,2020,27(6):76-78.
[24] Zhou JM,Liang R,Zhu SY,et al. LncRNA WWC2-AS1 functions AS a novel competing endogenous RNA in the regulation of FGF2 expression by sponging miR-16 in radiation-induced intestinal fibrosis [J]. BMC Cancer,2019,19(1):54-62.
[25] Liguori TTA,Liguori GR,Liguori LFP,et al. Fibroblast growth factor-2,but not the adipose tissue-derived stromal cells secretome,inhibits TGF-β1-induced differentiation of human cardiac fibroblasts into myofibroblasts [J]. Sci Rep,2018,8(1):1-10.
[26] 孙雪林,张亚同,陈頔,等.SMYD2对心脏成纤维细胞的增殖和胶原合成的影响[J].中国心血管杂志,2020, 25(2):175-179.
[27] Presta M,Foglio E,Schuind AC,et al. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2 [J]. Front Immunol,2018,9(1):2327-2327. |
|
|
|